TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in prevalence of Externalising Disorders in Children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parent Daily Ratings: oppositional and aggressive sub scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevention of new lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Healing of existing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence of a delayed graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Yale Brown Obsessive Compulsive Scale (Modified for BDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in professional quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of excessive weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat Free Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients Who Gained Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: percentages of positive responses to questions 2 and 3 in SEP diary
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Patient-reported Quality of Life - Cancer specific
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Patient-reported Quality of Life - General
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Consonant Nucleus Consonant (CNC) Monosyllabic Word Score-Treated Ear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AzBio Sentence Score in Noise - Treated Ear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4+ (T-helper cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD8+ (T-cytotoxic cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PD-1 on CD8+ and CD4+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD28+ and CD3+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Angiostatin production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients showing improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Oral Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in number of rosacea inflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent of participants showing treatment success (IGA score of 0 or 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: MHC class II expression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: total amount of morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post operative shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of facial angiofibroma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Weekly Average Number of Completely Spontaneous Bowel Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increased alcohol-specific help-seeking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: all causes mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change of Lung to liver Elastography ratio (LLE ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HIV risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants completing study procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Qualitative assessment of image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative assessment of image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of metal ions in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of patients with neurological deterioration under hospital treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of patients with new ischemic stroke under hospital treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of patients with symptomatic hemorrhagic transformation of an ischemic stroke under hospital treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of patients with symptomatic intracranial hemorrhage under hospital treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of patients with myocardial infarction under hospital treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of patients with coronary revascularization without myocardial infarction under hospital treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Partial Remission (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change in the prevalence of bowel symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change in the severity of intestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: [11C]-(+)-PHNO binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of FCH-PET-CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who experience adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Secreted markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nanovesicles production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of quality controls within nominal value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Lispro Area Under the Concentration Curve Zero to Seven Hours (AUC0-7hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Survival of stomach cancer
Endpoint domain: Mortality/survival
Primary endpoint: Masseter muscle tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Geometric Mean Titers Against Gardasil Vaccine HPV Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers Against Parental Dengue Virus Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acceptability of HNFC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physician observer scar assessment score (POSAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Width of the scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Presence of myocardial ischemia assessed by myocardial perfusion PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of myocardial ischemia assessed by cardiopulmonary exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of orthostatic hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Culture result of Mycobacteria in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to the first occurrence of a skeletal related event (SRE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Functional Remission of General Schizophrenia Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subjective Recovery Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Failure of high flow nasal canula (HFNC) at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of treatment sessions attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Traumatic Childbirth Perception Scale (TCPS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change on I-PSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity Score Erythrocyte Sedimentation Rate (DAS28-ESR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of DAA therapy within 12 weeks
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of SARS-CoV-2 antibody positive patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Left Upper Extremity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Right Upper Extremity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Left Lower Extremity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Right Lower Extremity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in RQLQ Score From Baseline to Two Weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Percent Eosinophils From Baseline to Two Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean thickness of postganglionic fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modified Rankin Disability Score (mRS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Detection of somatic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Premature ovarian failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes in lung perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in cannabis use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum change in airway responsiveness to AMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Change in Best-Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Best Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced prevalence of scabies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduced prevalence of skin sores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: serum creatine kinase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: DNA Integrity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Range of motion in degrees of the wrists
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Circumlimbal Conjunctival Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variation in the level of joint function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: H-reflex analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of dialysis-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of PD-L1 expression analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of MMR status analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver blood flow and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in testicular volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in haemodynamic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Global survival (GS)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of occurrence of anemia and thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Median diaphragm excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of documented COVID-19
Endpoint domain: Adverse events/effects
Primary endpoint: Change in SCORAD total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Seroconversion Rate 21 Days After First Study Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion Rate 21 Days After Second Study Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After First Study Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After Second Study Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of children with tuberculosis correctly identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of tuberculosis negative children correctly identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Participant's subjective rating of comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant's subjective rating of vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant's subjective rating of lens handling
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from flow-mediated dilation (FMD) at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Visual Acuity (LogMAR Letters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of late effects
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in gastrointestinal quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in depressive symptoms [HAM-D - total score]
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in overall psychological distress [SCL-90-R9 - GSI]
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Timely diagnosis of melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional anti-Zika antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urinary catabolites of PACs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mesh attachment interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Neuromuscular monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Optimal on-time adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Conjunctival vascularity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Successful Treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerable Device-related Toxicity Profile
Endpoint domain: Adverse events/effects
Primary endpoint: Whole-mouth Mean Modified Gingival Index (MGI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-mouth Mean Plaque Index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking distance from the 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visceral Adipose Tissue Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AAA prevalence
Endpoint domain: Mortality/survival
Primary endpoint: Post-lunch cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Adherence to vaginal dilation therapy after radiotherapy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Toxicity symptoms (vomiting or diarrhea)
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of female sexual response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: biochemical relapse-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: change in gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in abdominal visceral fat thickness (VFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bowel movement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sensitivity of the improved Basophil Activation Test (BAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specificity of the improved Basophil Activation Test (BAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of [6R]-5,10-methylene-THF in Tumor Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of [6R]-5,10-methylene-THF in Adjacent Mucosa Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of [6S]-5-THF in Tumor Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of [6S]-5-THF in Adjacent Mucosa Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Had at Least One Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Had at Least One AE Attributed to the Study Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Withholding of Second Vaccine Dose Due to Adverse Reactions Attributed to First Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Pregnant Women With a Hemagglutination Inhibition (HAI) Titer of >= 40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 and Grade 4 Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment Emergent Malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of Rituximab infusions
Endpoint domain: Adverse events/effects
Primary endpoint: Inflation volume of the silicone expander
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in muscle insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Social outcome
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in catheter blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of pump pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aluminum rate in teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of Retinal Thinning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: dislocation rates
Endpoint domain: Adverse events/effects
Primary endpoint: MDRB eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes